GUIDELINES FOR CLINICAL-TRIALS IN SYSTEMIC-SCLEROSIS (SCLERODERMA) .1. DISEASE-MODIFYING INTERVENTIONS

被引:108
作者
WHITE, B
BAUER, EA
GOLDSMITH, LA
HOCHBERG, MC
KATZ, LM
KORN, JH
LACHENBRUCH, PA
LEROY, EC
MITRANE, MP
PAULUS, HE
POSTLETHWAITE, AE
STEEN, VD
机构
[1] UNIV MARYLAND,SCH MED,BALTIMORE,MD 21201
[2] VET ADM MED CTR,BALTIMORE,MD 21218
[3] STANFORD UNIV,MED CTR,STANFORD,CA 94305
[4] UNIV ROCHESTER,MED CTR,ROCHESTER,NY 14642
[5] US FDA,PILOT DRUG EVALUAT STAFF,ROCKVILLE,MD 20857
[6] BOSTON UNIV,SCH MED,BOSTON,MA 02118
[7] BOSTON VA MED CTR,BOSTON,MA
[8] UNIV CALIF LOS ANGELES,LOS ANGELES,CA
[9] MED UNIV S CAROLINA,CHARLESTON,SC 29425
[10] US FDA,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20857
[11] UNIV TENNESSEE,SCH MED,MEMPHIS,TN
[12] VET ADM MED CTR,MEMPHIS,TN 38104
[13] UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA
来源
ARTHRITIS AND RHEUMATISM | 1995年 / 38卷 / 03期
关键词
D O I
10.1002/art.1780380309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To develop guidelines for therapeutic trials designed to improve the overall course of systemic sclerosis (SSc), that is, to reduce the development of significant organ damage or death, Methods, A committee developed general guidelines for patient inclusion and exclusion criteria, randomization, blinding of patients and physicians, controls, duration of the trial, investigator training, responses, samples size, study dropouts, statistical analyses, data management, and safety monitoring, Delphi and nominal group techniques were used. Results. Briefly, patients with diffuse cutaneous SSc of less than 24 months' duration should be included because they are at greatest risk for the development of severe organ damage and death, Patients should be excluded if they have other connective tissue diseases, SSc-like illnesses related to exposures or ingestions, severe existing internal organ damage, an unacceptable risk of side effects, dr concurrent therapies that might independently influence the outcome, Randomized, double-blind, placebo-controlled trials are preferred, The treatment and followup period must be long enough to permit observation of any disease modification, which is likely to require 18-36 months, unless an extraordinarily effective therapy is identified, Responses selected should be quantitative, consistently add accurately reflect activity of SSc in major target organs (not solely the skin), be sensitive to change, and be standardized, with limited variability, An example of a set of responses is given, Surrogate responses are desirable, but none have been validated as correlating with organ damage. Conclusion, Guidelines have been established for trials of disease-modifying interventions in SSc, These guidelines will need to be altered as additional information becomes available. Any given protocol will be individualized based on the nature of the intervention and objectives of the study, Nonetheless, each study team should develop a protocol that meets the spirit of these guidelines.
引用
收藏
页码:351 / 360
页数:10
相关论文
共 25 条
[1]   ECONOMIC-ANALYSIS IN RANDOMIZED CONTROL TRIALS [J].
ADAMS, ME ;
MCCALL, NT ;
GRAY, DT ;
ORZA, MJ ;
CHALMERS, TC .
MEDICAL CARE, 1992, 30 (03) :231-243
[2]  
BARNETT AJ, 1988, J RHEUMATOL, V15, P276
[3]  
BRENNAN P, 1992, BRIT J RHEUMATOL, V31, P457
[4]   EARLY UNDIFFERENTIATED CONNECTIVE-TISSUE DISEASE .3. OUTCOME AND PROGNOSTIC INDICATORS IN EARLY SCLERODERMA (SYSTEMIC-SCLEROSIS) [J].
BULPITT, KJ ;
CLEMENTS, PJ ;
LACHENBRUCH, PA ;
PAULUS, HE ;
PETER, JB ;
AGOPIAN, MS ;
SINGER, JZ ;
STEEN, VD ;
CLEGG, DO ;
ZIMINSKI, CM ;
ALARCON, GS ;
LUGGEN, ME ;
POLISSON, RP ;
WILLKENS, RF ;
READING, JC ;
WILLIAMS, HJ ;
WARD, JR .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (08) :602-609
[5]  
Callahan L F, 1989, Arthritis Care Res, V2, P122, DOI 10.1002/anr.1790020406
[6]   SKIN SCORE - A SEMIQUANTITATIVE MEASURE OF CUTANEOUS INVOLVEMENT THAT IMPROVES PREDICTION OF PROGNOSIS IN SYSTEMIC-SCLEROSIS [J].
CLEMENTS, PJ ;
LACHENBRUCH, PA ;
NG, SC ;
SIMMONS, M ;
STERZ, M ;
FURST, DE .
ARTHRITIS AND RHEUMATISM, 1990, 33 (08) :1256-1263
[7]   HOW STUDY DESIGN AFFECTS OUTCOMES IN COMPARISONS OF THERAPY .1. MEDICAL [J].
COLDITZ, GA ;
MILLER, JN ;
MOSTELLER, F .
STATISTICS IN MEDICINE, 1989, 8 (04) :441-454
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]  
DERSIMONIAN R, 1984, NEW ENGL J MED, V311, P442
[10]   RANDOMIZATION DESIGNS IN COMPARATIVE CLINICAL-TRIALS [J].
ELLENBERG, SS .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1404-1408